Top

Published in:

Open Access 01-12-2021 | Fatty Liver | Research

Microecological preparation combined with an modified low-carbon diet improves glucolipid metabolism and cardiovascular complication in obese patients

Authors: Jianguo Liu, Liehui Xiao, Hezhongrong Nie, Yong Pan, Yan Liu, Zhentian Zhang, Xiuping Lin, Yuan Zhang, Jinchuang Cai, Muxiu Yang, Yajing Liu, Leijun Zhang, Aimin Xu, Cuifeng Zhu

Published in: Diabetology & Metabolic Syndrome | Issue 1/2021

Abstract

Objective

To investigate the impact of microecological preparation combined with modified low-carbon diet on the glucolipid metabolism and cardiovascular complication in obese patients.

Methods

From August 2017 to July 2020, 66 obese patients were recruited, and administrated with an modified low-carbon diet with (group A) or without (Group B) microecology preparation and a balanced diet in control group (group C) for 6 months. Meanwhile, 20 volunteers administrated with a balanced diet were recruited as the healthy control group (group D).

Results

After 6-month intervention, obese subjects in group A and B showed significant improvement of body and liver fat mass, reduction of serum lipid levels, intestinal barrier function markers, insulin resistance index (IRI), high blood pressure (HBP) and carotid intima thickness, as compared with subjects in group C. More importantly, subjects in group A had better improvement of vascular endothelial elasticity and intimal thickness than subjects in group B. However, these intervention had no effect on carotid atherosclerotic plaque.

Conclusion

Administration of microecological preparation combined with modified low-carbon diet had better improvement of intestinal barrier function, glucose and lipid metabolism, and cardiovascular complications than low-carbon diet in obese patients, but the effect of a simple low-carb diet on carotid atherosclerotic plaque need to be further addressed.

Matthias B. Nature reviews endocrinology, obesity: global epidemiology and pathogenesis. Doi: https://doi.org/10.1038/s41574-019-0176-8. Abstract & Authors, Review 2019–02–27.

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2016; 387: 1377–96.

Zhou HC, et al. Effectiveness of different waist circumference cut-off values in predicting metabolic syndrome prevalence and risk factors in adults in China. Biomed Environ Sci. 2014;27(5):325–34. https://doi.org/10.3967/bes2014.057.CrossRefPubMed

Li S, et al. Bmi and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. J Diab Compl. 2014;28(4):470–6. https://doi.org/10.1016/j.jdiacomp.2014.03.015.CrossRef

Gadde KM, et al. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. https://doi.org/10.1016/j.jacc.2017.11.011.CrossRefPubMedPubMedCentral

O’Neill B, Raggi P. The ketogenic diet: pros and cons. Atherosclerosis. 2020;292:119–26. https://doi.org/10.1016/j.atherosclerosis.2019.11.021.CrossRefPubMed

Gregg W, Shaw JE. Global health effects of over-weight and obesity. N Engl J Med. 2017;377(1):80–1.CrossRef

Bartolomaeus H, et al. Gut-heart axis: how gut bacteria influence cardiovascular diseases. Herz. 2020;45(2):134–41. https://doi.org/10.1007/s00059-020-04897-0.CrossRefPubMed

Lai ZL, et al. Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. Sci Rep. 2018;8(1):15625. https://doi.org/10.1038/s41598-018-33893-y.CrossRefPubMedPubMedCentral

10.

Wang Y, Wang H, Howard AG, Tsilimigras MCB, Avery CL, Meyer KA, Sha W, Sun S, Zhang J, Su C, Wang Z, Fodor AA, Zhang B, Gordon-Larsen P. Gut microbiota and host plasma metabolites in association with blood pressure in Chinese adults. Hypertension. 2021;77(2):706–17. https://doi.org/10.1161/HYPERTENSIONAHA.120.16154.CrossRefPubMed

11.

Chooi YC, et al. The epidemiology of obesity. Metabolism. 2019;92:6–10. https://doi.org/10.1016/j.metabol.2018.09.005.CrossRefPubMed

12.

Zhang X, Zhang M, Zhao Z, et al. Geographic variation in prevalence of adult obesity in China: results from the 2013–2014 National Chronic Disease and Risk Factor Surveillance. Ann Intern Med. 2019;8:54.

13.

Healthy China action promotion committee. Healthy China action (2019–2030): overall requirements, major actions and key indicators. China journal of circulation. 2019;34:846–58.

14.

Being overweight wipes 4 years from life, new report reveals. Medscape, 2019.

15.

The heavy burden of obesity: the economics of prevention. OECD Health Policy Studies, 2019.

16.

Ting R, et al. Ketogenic diet for weight loss. Can Fam Physician. 2018;64(12):906.PubMedPubMedCentral

17.

Shi H, Yu K, Zhou H. low carbon diet, cancer metabolism and nutrition. Electr J. 2019;6:1–6.

18.

Zaved Waise TM, Rasti M, Duca FA, Zhang SY, Bauer PV, Rhodes CJ, Lam TKT. Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production. Nat Commun. 2019;10:714. https://doi.org/10.1038/s41467-019-08582-7.CrossRef

19.

Masino SA, David N. Ruskin, ketogenic diets and pain. J Child Neurol. 2013;28(8):993–1001. https://doi.org/10.1177/0883073813487595.CrossRefPubMedPubMedCentral

20.

Sartorius K, Sartorius B, Madiba TE, et al. Does highcarbohydrate intake lead to increased risk of obesity? A systematic review and meta-analysis. BMJ Open. 2018;8: e018449. https://doi.org/10.1136/bmjopen-2017-018449.CrossRefPubMedPubMedCentral

21.

Bravata DM, Sanders I, Huang J, Krumholz HM, Olkin I, Gardner CD, Bravata DM. Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA. 2003;289(14):1837–50.CrossRef

22.

Brinkworth GD, et al. Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br J Nutr. 2009;101(10):1493–502. https://doi.org/10.1017/s0007114508094658.CrossRefPubMed

23.

Williams EP, Mesidor M, Winters K, Dubbert PM, Wyatt SB. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4(3):36370. https://doi.org/10.1007/s13679-015-0169-4.CrossRef

24.

Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54. https://doi.org/10.1038/s41577-019-0198-4.CrossRefPubMed

25.

Gupta L, et al. Ketogenic diet in endocrine disorders: current perspectives. J Postgrad Med. 2017;63(4):242–51.CrossRef

26.

Peng J, et al. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018;214:153–7. https://doi.org/10.1016/j.lfs.2018.10.063.CrossRefPubMed

27.

Wang B, et al. The human microbiota in health and disease. Engineering. 2017;3:71–82. https://doi.org/10.1016/J.ENG.2017.01.008.CrossRef

28.

Gill PA, et al. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment Pharmacol Ther. 2018;48(1):15–34. https://doi.org/10.1111/apt.14689.CrossRefPubMed

29.

Kitai T, WilsonTang WH. Gut microbiota in cardiovascular disease and heart failure. Clin Sci. 2018;132:85–91. https://doi.org/10.1042/CS20171090.CrossRef

30.

Liu Z, Ma Y, Wen D. Advances in the treatment and mechanism of probiotics and probiotics on obesity. Chinese J Microecol. 2008;30(9):1096–101.

31.

Salminen S, et al. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek. 1996;70(2):347–58. https://doi.org/10.1007/BF00395941.CrossRefPubMed

32.

Brusaferro A, Cozzali R, Orabona C, Biscarini A, Farinelli E, Cavalli E, et al. Is it time to use probiotics to prevent or treat obesity? Nutrients. 2018;10(11):E1613. https://doi.org/10.3390/nu10111613.CrossRefPubMed

33.

Patel R, Dupont HL. New approaches for bacteriotherapy : Prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015;60(Suppl 2):S108-121.CrossRef

34.

Martens EC, Neumann M, Desai MS. Interactions of commensal and patho-genic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018;16(8):457. https://doi.org/10.1038/s41579-018-0036-x.CrossRefPubMed

35.

Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3(3):207. https://doi.org/10.1016/S2213-8587(14)70134-2.CrossRefPubMed

36.

Interplay between the human gut microbiome and host metabolism. Nat Commun. 2019. Doi: https://doi.org/10.1038/s41467-019-12476-z.

37.

The gut microbiome influences host endocrine functions. Endocr Rev. 2019. https://doi.org/10.1210/er.2018-0028005-13.CrossRef

38.

Wang B, et al. Glutamine and intestinal barrier function. Amino Acids. 2015;47(10):2143–54. https://doi.org/10.1007/s00726-014-1773-4.CrossRefPubMed

Title: Microecological preparation combined with an modified low-carbon diet improves glucolipid metabolism and cardiovascular complication in obese patients
Authors: Jianguo Liu
Liehui Xiao
Hezhongrong Nie
Yong Pan
Yan Liu
Zhentian Zhang
Xiuping Lin
Yuan Zhang
Jinchuang Cai
Muxiu Yang
Yajing Liu
Leijun Zhang
Aimin Xu
Cuifeng Zhu
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Fatty Liver
Published in: Diabetology & Metabolic Syndrome / Issue 1/2021
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-021-00697-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Advances in GLP-1 treatment: focus on oral semaglutide

Exercise improves bone formation by upregulating the Wnt3a/β-catenin signalling pathway in type 2 diabetic mice

Arterial stiffness and progression of cerebral white matter hyperintensities in patients with type 2 diabetes and matched controls: a 5-year cohort study

Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients

Increased serum asprosin is correlated with diabetic nephropathy

Ethnic disparity in metabolic syndrome and related obesity and health behavior: a community study in Taiwan

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials